MRI Reveals Altered Brain Structure in Fetuses Exposed to Alcohol

In the first MRI-based study to investigate pre-natal alcohol exposure, researchers found significant changes in the brain structure of fetuses exposed to alcohol compared to healthy controls. Results of the study are being presented today at the annual meeting of the Radiological Society of North America (RSNA).

“Fetal alcohol syndrome is a worldwide problem in countries where alcohol is freely available,” said Gregor Kasprian, M.D., associate professor of radiology at the Medical University of Vienna in Austria. “It’s estimated that 9.8% of all pregnant women are consuming alcohol during pregnancy, and that number is likely underestimated.”

Fetal alcohol syndrome is the most severe form of a group of conditions called fetal alcohol spectrum disorders that result from alcohol exposure during pregnancy. Babies born with fetal alcohol spectrum disorders may have specific physical features, learning disabilities, behavioral problems or speech and language delays. According to Dr. Kasprian, one in 70 pregnancies with alcohol exposure results in fetal alcohol syndrome.

“There are many postnatal studies on infants exposed to alcohol,” Dr. Kasprian said. “We wanted to see how early it’s possible to find changes in the fetal brain as a result of alcohol exposure.”

For the study, researchers recruited 500 pregnant women who were referred for a fetal MRI for clinical reasons. On an anonymous questionnaire, 51of the women admitted to consuming alcohol during their pregnancy. The questionnaires used were the Pregnancy Risk Assessment Monitoring System (PRAMS), a surveillance project of the Centers for Disease Control and Prevention and health departments, and the T-ACE Screening Tool, a measurement tool of four questions that identify risk drinking.

“We provided a safe environment where women could feel comfortable honestly answering the questions,” Dr. Kasprian said.

After eliminating some of the fetal MRIs for reasons such as structural brain anomalies and/or poor image quality, the final study group consisted of 26 fetal MRI exams from 24 alcohol-positive fetuses and a control group of 52 gender- and age-matched healthy fetuses. At the time of imaging, fetuses ranged in age between 20 and 37 weeks.

The researchers used super-resolution imaging, which allowed them to create one dataset to re-construct each fetal brain. Next, they completed an analysis of 12 different brain structures, computing total brain volume and segment volumes of specific brain compartments.

“One of the main hallmarks of our study is that we investigated so many smaller sub-compartments of the brain,” said co-author Marlene Stuempflen, M.D., scientific researcher at the Medical University of Vienna.

The statistical analysis revealed two major differences in the alcohol-exposed fetuses compared to healthy controls: an increased volume in the corpus collosum and a decreased volume in the periventricular zone.

“This is the first time that a prenatal imaging study has been able to quantify these early alcohol-associated changes,” Dr. Stuempflen said.

The corpus collosum is the main connection between the brain’s two hemispheres. Dr. Stuempflen noted that it is fitting that this very central structure is affected, because the clinical symptoms of fetal alcohol spectrum disorders are highly heterogenous, or diverse, and cannot be pinpointed to one specific substructure of the brain.

“The changes found in the periventricular zone, where all neurons are born, also reflect a global effect on brain development and function,” she said.

The researchers said finding a thicker corpus collosum in the alcohol-positive fetuses was surprising because the corpus collosum is thinner in infants with fetal alcohol spectrum disorders.

“It appears that alcohol exposure during pregnancy puts the brain on a path of development that diverges from a normal trajectory,” Dr. Kasprian said. “Fetal MRI is a very powerful tool to characterize brain development not only in genetic conditions, but also acquired conditions that result from exposure to toxic agents.”

Additional co-authors are Ernst Schwartz, M.Sc., Mariana Diogo, M.D., Ph.D., Sarah Glatter, M.D., M.M.Sc., Birgit Pfeiler, Victor Schmidbauer, M.D., Lisa Bartha-Doering, Ph.D., Rainer Seidl, M.D., Elisabeth Krampl-Bettelheim, M.D., and Daniela Prayer, M.D.

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.
"Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes," said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world's most prestigious, breast cancer-focused organizations."
Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).
The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.
“These study results are highly encouraging especially given the short treatment duration of 10 days with BX004,” said Jonathan Solomon, Chief Executive Officer of BiomX. “In Part 2 of the study, BX004 showed clinically meaningful improvement in pulmonary function compared to placebo, as measured by relative FEV11 improvement (5.67% at Day 17, 1 week after end of treatment) and Cystic Fibrosis Questionnaire-Revised (CFQ-R) respiratory domain (8.87 points at Day 17) in a predefined subgroup of patients with reduced lung function.”  

By using this website you agree to accept Medical Device News Magazine Privacy Policy